Sage Journals: Discover world-class research

Abstract

Background:

Mesenchymal stem cells (MSCs) exhibit immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animals. Clinical trials in several human conditions support the safety and efficacy of MSC transplantation. Published experience in multiple sclerosis (MS) is modest.

Objective:

To assess feasibility, safety, and tolerability and explore efficacy of autologous MSC transplantation in MS.

Methods:

Participants with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), Expanded Disability Status Scale score 3.0–6.5, disease activity or progression in the prior 2 years, and optic nerve involvement were enrolled. Bone-marrow-derived MSCs were culture-expanded and then cryopreserved. After confirming fulfillment of release criteria, 1–2 × 10⁶ MSCs/kg were thawed and administered IV.

Results:

In all, 24 of 26 screened patients were infused: 16 women and 8 men, 10 RRMS and 14 SPMS, mean age 46.5, mean Expanded Disability Status Scale score 5.2, 25% with gadolinium-enhancing magnetic resonance imaging (MRI) lesions. Mean cell dosage (requiring 1–3 passages) was 1.9 × 10⁶ MSCs/kg (range, 1.5–2.0) with post-thaw viability uniformly ⩾95%. Cell infusion was tolerated well without treatment-related severe or serious adverse events, or evidence of disease activation.

Conclusion:

Autologous MSC transplantation in MS appears feasible, safe, and well tolerated. Future trials to assess efficacy more definitively are warranted.

Keywords

Multiple sclerosis clinical trial mesenchymal stem cells safety disability measures quantitative MRI

Get full access to this article

View all access options for this article.

References

Cohen

. Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci 2013; 333: 43–49.

Connick

Kolappan

Crawley

et al . Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11: 150–156.

Llufriu

Sepulveda

Blanco

et al . Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE 2014; 9: e113936.

Lazarus

Haynesworth

Gerson

et al . Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557–564.

ICH harmonised tripartite guideline: Guideline for good clinical practice—E6(R1). International conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, 10 June 1996, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 28 September 2014).

World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects, http://www.wma.net/en/30publications/10policies/b3/index.html (accessed 22 August 2016).

Polman

Reingold

Banwell

et al . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol 2011; 69: 292–302.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452.

Swanton

Rovira

Tintore

et al . MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol 2007; 6: 677–686.

10.

Lalu

McIntyre

Pugliese

et al . Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS ONE 2012; 7: e47559.

11.

Coles

Wing

Smith

et al . Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1995; 354: 1691–1695.

12.

Bielekova

Goodwin

Richert

et al . Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167–1175.

13.

The Lenercept Multiple Sclerosis Study Group; The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457–465.

14.

Freedman

Bar-Or

Atkins

et al . The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. Mult Scler 2010; 16: 503–510.

15.

Le Blanc

Frassoni

Ball

et al . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579–1586.

16.

Koc

Day

Nieder

et al . Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215–222.

17.

Harris

Yan

Vyshkina

et al . Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci 2012; 313: 167–177.

18.

Cogle

Yachnis

Laywell

et al . Bone marrow transdifferentiation in brain after transplantation: A retrospective study. Lancet 2004; 363: 1432–1437.

19.

Lee

Kim

H-S

et al . A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72: 32–40.

20.

Karussis

Karageorgiou

Vaknin-Dembinsky

et al . Safety and immunologic effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67: 1187–1194.

21.

Moyeddin Bonab

Yazdanbakhsh

Loft

et al . Does mesenchymal stem cell therapy help multiple sclerosis patients? Iran J Immunol 2007; 4: 50–57.

22.

Yamout

Hourani

Salti

et al . Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 2010; 227: 185–189.

23.

Chinnadurai

Copland

Garcia

et al . Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells 2016; 34: 2429–2442.

24.

Francois

Copland

Yuan

et al . Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy 2012; 14: 147–152.

25.

Moll

Alm

Davies

et al . Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells 2014; 32: 2430–2442.

26.

Chinnadurai

Garcia

Sakurai

et al . Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Stem Cell Reports 2014; 3: 60–72.

27.

Reese

Hooper

Lazarus

et al . Identification of an alternative to fetal bovine serum for the culture expansion of human mesenchymal stem cells for use in clinical studies (P901). Mult Scler J 2014; 20(Suppl. 1): 461.

28.

Rasmusson

Uhlin

Le Blanc

et al . Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 2007; 82: 887–893.

29.

Eliopoulos

Stagg

Lejeune

et al . Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005; 106: 4057–4065.

30.

Papadaki

Tsagournisakis

Mastorodemos

et al . Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant 2005; 36: 1053–1063.

31.

Mazzanti

Aldinucci

Biagioli

et al . Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implications for assessment of disease activity and treatment. J Neuroimmunol 2008; 199: 142–150.

32.

Mallam

Kemp

Wilkins

et al . Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler 2010; 16: 909–918.

33.

De Oliveira

GLV

de Lima

KWA

Colombini

et al . Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. Cell Transplant 2015; 24: 151–165.

34.

Sarkar

Redondo

Kemp

et al . Reduced expression of mitochondrial fumarate hydratase contributes to impaired MSC-mediated neuroprotection in multiple sclerosis. Mult Scler J 2016; 22(S3): 38–39.

35.

Redondo

Sarkar

Kemp

et al . Alterations in the secretome of MSCs isolated from patients with MS are in keeping with their reduced neuroprotective potential under conditions of oxidative stress. Mult Scler J 2016; 22(S3): 321.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material